News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase II
Biota Pharmaceuticals, Inc. (BOTA) Stock Crashes As Influenza Drug Laninamivir Octanoate Fails Mid-Stage Trial; Stock Down -20.54% At 11:37AM ET 8/1/2014
Novartis AG (NVS) Malaria Pill KAE609 Shows Promise As Best Drugs Fail 8/1/2014
Kala Pharmaceuticals Initiates Phase 2 Clinical Trial To Evaluate LE-MPP (KPI-121) In Patients With Retinal Vein Occlusion And Diabetic Macular Edema 7/31/2014
NOXXON Pharma AG Initiates Phase IIa Study Of Anti-Hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) In Dialysis Patients With EPO-hyporesponsive Anemia 7/31/2014
Expanded Data On Disability And Cognitive Improvements In Phase 2 Study Of Synthetic Biologics, Inc. (SYN)' Trimesta™ In Multiple Sclerosis To Be Presented At 2014 Joint ACTRIMS-ECTRIMS Meeting 7/31/2014
CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV 7/31/2014
BioTie Therapies Corp. Updates Outlook On Tozadenant And SYN120 7/30/2014
Amarantus BioSciences, Inc. Amends LymPro LP-002 Clinical Protocol to Report Interim Data at Presentation 7/30/2014
RXi Pharmaceuticals (RXII) Expands Clinical Program With Initiation Of Third Phase 2a Study With RXI-109 For Treatment Of Hypertrophic Scars 7/30/2014
Immune Pharmaceuticals, Inc. Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 7/30/2014
Quark Pharmaceuticals Inc. Reports Favorable Data From Phase 2 Clinical Trial Evaluating Investigational siRNA QPI-1002 7/29/2014
Neurotrope Initiates Phase 2a Study Of Bryostatin For The Treatment Of Alzheimer's Disease - Doses First Patients 7/29/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1103 Acromegaly Phase 2 Trial Dosing Completed 7/29/2014
EMD Serono Initiates Phase 2 Study Of Anti-PD-L1 Antibody MSB0010718C In Metastatic Merkel Cell Carcinoma 7/29/2014
Quark Pharmaceuticals Inc. Reports Favorable Results From Phase 2 Clinical Trial Evaluating Investigational Sirna QPI-1002 7/28/2014
ERYtech Pharma Announces Enrollment Of First Patient In Phase II Study Of ERY-ASP In Pancreatic Cancer 7/28/2014
Phase 2 COSMOS Study Results Published In The Lancet Demonstrate Efficacy And Safety Of Janssen’s Once-Daily Simeprevir In All Oral 12-Week Combination With Sofosbuvir For Genotype 1 Chronic Hepatitis C 7/28/2014
Medivir AB (MVRBF): Phase II COSMOS Study Results Published In Lancet On World Hepatitis Day 7/28/2014
Retroscreen Conducts Landmark hVIVO Human Challenge Model Study Of AL-8176 In RSV For Alios BioPharma 7/28/2014
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 7/28/2014
MorphoSys AG Provides Update On The Company's Proprietary Drug Portfolio 7/28/2014
Innapharma: Completion Of Target Enrollment In The Phase 2 EffiKIR Trial 7/24/2014
Celsion Corporation (CLSN) Announces Positive Interim Data Update From Its Phase 2 DIGNITY Study In Breast Cancer 7/24/2014
Alios BioPharma Reports Positive Results Of Its Anti-RSV Nucleoside Analog AL-8176 In A Phase 2 Challenge Study In Adults Infected With Respiratory Syncytial Virus (RSV) 7/24/2014
Esperion Therapeutics, Inc. (ESPR) Announces Initiation Of A Phase 2 Clinical Study Of ETC-1002 In Patients With Hypercholesterolemia And Hypertension 7/24/2014
Aduro Biotech Receives Breakthrough Therapy Designation From FDA For Innovative Pancreatic Cancer Combination Immunotherapy 7/23/2014
Inovio Pharmaceuticals (INO) HPV Immunotherapy Achieves Primary Efficacy Endpoint In Randomized Phase 2 Cervical Dysplasia Trial 7/23/2014
Biotron Limited (BIT:AU) BIT225 Reverses HIV-Induced Impairment Of The Immune System 7/23/2014
SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus 7/22/2014
ZIOPHARM, Inc. Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And Clinical Program Update 7/22/2014
Halozyme Therapeutics, Inc. (HALO) Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 7/22/2014
ERYtech Pharma Announces Enrollment Of First Patient In Phase I/II Study Of ERY-ASP In Acute Lymphoblastic Leukemia In The United States 7/22/2014
Enrollment Commences In NeuroSigma, Inc.-Sponsored Pediatric Clinical Trial For The Treatment Of Lennox-Gastaut Syndrome 7/22/2014
Genocea Biosciences HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses In Vaccinated Subjects 7/22/2014
Argos Therapeutics, Inc. (ARGS) Presents Data Showing The Impact Of HIV Antigen Sequence Divergence On Durable Viral Control Following Treatment With Autologous Immune Therapy 7/22/2014
GANYMED Pharmaceuticals AG Completes Recruitment For Randomized Phase 2 FAST Trial Of IMAB362 For Gastroesophageal Cancer 7/22/2014
Advaxis, Inc. And MedImmune (AZN) Partner On Immuno-Oncology Combination Clinical Trial 7/22/2014
CASI Pharmaceuticals  (ENMD) To Start China Trial Of Cancer Drug 7/21/2014
Can-Fite BioPharma (CFBI) CEO To Deliver Scientific Presentation And Serve On Expert Panel At Purines 2014 In Bonn, Germany On July 23-27, 2014 7/21/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014
Anavex Life Sciences Corp. (AVXL.OB) Achieves Key Milestone As It Secures Cgmp Manufacturing For Drug Candidate Trial Supplies 7/21/2014
AVANIR Pharmaceuticals (AVNR) Announces FDA Acceptance Of IND For AVP-786 For The Adjunctive Treatment Of Major Depressive Disorder 7/21/2014
CASI Pharmaceuticals  (ENMD) Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With Enmd-2076 For Triple-Negative Breast Cancer In China 7/21/2014
Genocea Biosciences Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy 7/21/2014
Amarantus BioSciences, Inc. Discusses New Independent Peer-Reviewed Research Papers On MANF 7/18/2014
Roche (RHHBY) Alzheimer's Drug Crenezumab Fails Main Goals In Phase 2 Study 7/17/2014
Ruthigen Treats First Human Subjects In Clinical Trial For RUT58-60 7/17/2014
Juvenile Diabetes Research Foundation Partner ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces Key Project Milestone To Advance Innovative Encapsulated Cell Replacement Therapy Product For Type 1 Diabetes 7/17/2014
Synergy Pharmaceuticals Completes Patient Enrollment For Its SP-333 Phase 2 Trial In Patients With Opioid-Induced Constipation 7/17/2014
DBV Technologies Completes Last "Food Challenge" Visit Of Last Peanut-Allergic Patient In VIPES Phase 2b Clinical Study 7/17/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 2 Study Of ISIS-APO(a) Rx In Patients With High Lp(a) 7/17/2014
Auspex Pharmaceuticals Initiates Pivotal Phase 2/3 Clinical Trial For SD-809 In Tardive Dyskinesia 7/17/2014
Consortium Of Food Allergy Research Completes Recruitment Of National Institutes of Health (NIH)-Sponsored Cofar6 Phase 2Trial With DBV Technologies's Viaskin® Peanut In Treatment Of Peanut Allergy 7/17/2014
Targacept, Inc. (TRGT) Stops Alzheimer's Drug Trial After It Fails Phase 2b Trial 7/16/2014
BioTie Therapies Corp. Selects Bracket's CDR System™ For Phase 2 Trial Of Treatment Of Parkinson's Disease 7/16/2014
Resolve Therapeutics Initiates Phase 2 Clinical Study In SLE 7/16/2014
Adynxx Initiates Phase 2 Dose-Ranging Study Of AYX1, Lead Compound For The Prevention Of Post-Surgical Pain 7/16/2014
OncoMed Pharmaceuticals, Inc. (OMED) Initiates Randomized Phase 2 "ALPINE" Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) For Pancreatic Cancer 7/16/2014
CellAct Pharma Receives Orphan Drug Designation In EU For CAP7.1 In Biliary Tract Cancers 7/15/2014
Amarantus BioSciences, Inc. Announces Positive Clinical Performance And 7-Year Longitudinal Data Poster Presentations For Lympro Test® At AAIC 2014 7/15/2014
GenSpera Presents G-202 HCC Clinical Trial Update At 5th Asia-Pacific Primary Liver Cancer Expert Meeting 7/15/2014
Amarillo Biosciences (AMAR) Announces Positive Analytical Performance Data Poster Presentation For Lympro Test At AAIC 2014 7/14/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Studies Of VT-1161 With Moderate To Severe Interdigital Tinea Pedis 7/11/2014
Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Study Of VT-1161 In Patients With Moderate To Severe Acute Vulvovaginal Candidiasis 7/11/2014
Latest Sarepta Therapeutics (SRPT) Phase 2 Data Shows Greater Decline in Walking Ability For Muscular Dystrophy Patients 7/10/2014
Cytokinetics, Inc. (CYTK) Announced Additional Results Relating To Tirasemtiv From Pre-Specificed Subgroup Analyses Of BENEFIT-ALS 7/10/2014
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Tames Eczema In Phase 2b Trial 7/10/2014
Genticel’s Phase 2 Study With ProCervix Passes The Halfway Mark For Patient Recruitment 7/10/2014
SillaJen Lead Product Pexa-Vec Featured In "Nature Reviews Cancer" Article Summarizing The Potential Of Oncolytic Immunotherapy 7/10/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
Zafgen (ZFGN) Granted Orphan Drug Designation In The European Union For Beloranib, A First-In-Class Metap2 Inhibitor For The Treatment Of Prader-Willi Syndrome 7/10/2014
Boehringer Ingelheim Corporation's Breakthrough Cancer Drug Volasertib Effective In Phase 2 Trial 7/9/2014
NeoStem, Inc. Presents Five-Year Survival Data For Autologous Melanoma Immunotherapy Targeting Cancer Stem Cells At American Society of Clinical Oncology Annual Meeting 7/9/2014
Opko Health, Inc.'s Long-Acting Clotting Factor VIIa-CTP Receives Positive Opinion For Three Orphan Drug Designations In Europe 7/9/2014
480 Biomedical Awarded $1 Million Phase II NHLBI Contract To Advance Bioresorbable Scaffold For Pediatric Pulmonary Artery Stenosis 7/9/2014
Lexicon Pharmaceuticals, Inc. (LXRX) And Juvenile Diabetes Research Foundation Collaborate For Phase 2 Clinical Trial Of LX4211 In Type 1 Diabetes 7/9/2014
Adocia Announces Approval To Start A Phase IIa Clinical Study Of Hinsbet®, Its Fast-Acting Human Insulin, In Type 1 Diabetes 7/9/2014
Acasti Pharma Completes Phase 2 Double Blind (TRIFECTA) And Pharmacokinetic Trials 7/9/2014
National Institutes of Health (NIH) Funds Phase 2 Clinical Trial At University of California, Los Angeles (UCLA) For The Treatment Of ADHD With NeuroSigma, Inc.'s eTNS Systemnational 7/9/2014
Dignity Sciences Release: DS107E-02 - Positive Phase 2 Results In Atopic Dermatitis 7/8/2014
Synergy Pharmaceuticals Announces Successful End-Of-Phase 2 Meeting With FDA For Plecanatide In Irritable Bowel Syndrome With Constipation 7/8/2014
Oncolytics Biotech Inc. (ONC.TO) Announces Completion Of Patient Enrollment IN U.S. Randomized Phase 2 Pancreatic Cancer Study 7/8/2014
CardioCell Begins Phase IIa Clinical Trial Using itMSC Therapy To Treat Chronic Heart Failure (HF) Due To Non-Ischemic Cardiomyopathy 7/8/2014
Avraham Pharmaceuticals Ltd. Announces Successful Interim Results In Phase 2b Study Of Ladostigil For The Treatment Of MCI 7/8/2014
BioTie Therapies Corp.: Tozadenant Phase 2b Parkinson's Disease Study Published In Lancet Neurology 7/8/2014
PRC Clinical Completes Over 800 Monitoring Visits In Global Phase 2b Neurology Study 7/8/2014
Pluristem Therapeutics (PSTI) Initiates South Korean Arm of Multinational Phase 2 Intermittent Claudication Trial 7/8/2014
GenSpera To Present Ongoing HCC Trial Data At APPLE 2014 Congress July 12th In Taipei 7/7/2014
CASI Pharmaceuticals  (ENMD) Receives U.S. Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma 7/7/2014
Celladon Corporation Announces New Clinical Development Initiatives For MYDICAR® 7/7/2014
Amgen (AMGN) Wins FDA Breakthrough Therapy Designation For Investigational BiTE 7/3/2014
Agenus (AGEN)'s Brain Cancer Vaccine Doubles Survival Rate In Phase 2 Study 7/1/2014
Molecular Partners AG Release: Stage 3 Phase 2 Study Of DARPin Abicipar Pegol (Previously MP0112) Supports Progressing To Phase 3 Development Program 7/1/2014
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment 7/1/2014
Threshold Pharmaceuticals, Inc. (THLD) Initiates 440-Patient, Randomized, Double-Blind, Placebo-Controlled Trial Of TH-302 In Combination With Pemetrexed In Advanced Non-Squamous Non-Small Cell Lung Cancer 7/1/2014
Agenus (AGEN) Brain Cancer Vaccine Shows Extended Survival In Phase 2 Final Data Analysis 7/1/2014
AVANIR Pharmaceuticals (AVNR) Announces Two Data Presentations Related To Pseudobulbar Affect (PBA) At The Alzheimer's Association International Conference (AAIC) 7/1/2014
Ultragenyx Pharmaceuticals (RARE) Announces Initiation Of A Phase 2 Study Of KRN23 For Pediatric X-Linked Hypophosphatemia In The US And EU 7/1/2014
Quark Pharmaceuticals Inc. Announces Completion Of Phase 2 Trial Evaluating QPI-1002 For Prevention Of Delayed Graft Function In Kidney Transplant Patients 7/1/2014
Amunix, Inc. Congratulates Versartis, Inc. (VSAR) On Its Positive Phase 2a Results With VRS-317 6/30/2014
Northwestern Medicine Release: Researchers Seek to Tackle Transplant Tolerance Using Patients' Own T Cells 6/30/2014
Genervon Announces Biomarker Data From GALS-001 Clinical Trial For ALS 6/30/2014
Aclaris Therapeutics Announces Positive Results From Phase 2 Clinical Trial Of A-101 For The Removal Of Seborrheic Keratosis, A Common Type Of Skin Tumor 6/30/2014
TiGenix Announces The Clinical Development Of Cx611 In Early Rheumatoid Arthritis And Severe Sepsis 6/30/2014
Mologen AG (MOLGF.PK): Cancer Immune Therapy MGN1703 Shows Outstanding Long-Term Responses 6/30/2014
Ampio Pharmaceuticals, Inc. (AMPE) Initiates Study of Multiple Injections Of Ampion™ Into The Knees Of Patients With OA Of The Knee To Assess Its Healing And Cartilage Regeneration Effects 6/30/2014
Aclaris Therapeutics Announces Positive Results From Phase 2 Clinical Trial Of A-101 For The Removal Of Seborrheic Keratosis, A Common Type Of Skin Tumor 6/30/2014
Bellerophon Therapeutics Completes Enrollment Of Its Phase 2 Trial Of Inopulse® For Treatment Of Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) 6/27/2014
Burzynski Research Institute Announces Presentations At The 16th International Symposium On Pediatric Neuro-Oncology 6/27/2014
Aerie Pharmaceuticals, Inc. (AERI) Soars As Combo Eye Drug Roclatan Performs Well In Phase 2b Trial; Stock Up +28.29% At Market Close (June 25, 2014) 6/26/2014
Massachusetts' Agenus (AGEN) Touts Positive Phase 2 Data From HerpV Study 6/26/2014
Ischemix Enrolls First Patient In Phase 2a Trial To Prevent Contrast-Induced Acute Kidney Injury 6/26/2014
Agenus (AGEN) Vaccine Shows Significant Reduction In Viral Burden After HerpV Generated Immune Activation 6/26/2014
Basilea Pharmaceutica (BSLN.SW) Announces Start Of Phase 2a Study With Oncology Drug Candidate BAL101553 6/26/2014
Nora Pharma Announces Initiation Of Phase 2 RESPONSE Research Study 6/26/2014
Aurinia (ISA.TO) Initiates Phase 2b Clinical Trial Of Voclosporin To Treat Lupus Nephritis 6/26/2014
Alder Biopharmaceuticals Inc. Release: Data From Proof-Of-Concept Clinical Trial Of ALD403, A Monoclonal Antibody Against CGRP For The Prevention Of Migraine, To Be Presented At 56th Annual Scientific Meeting Of The American Headache Society 6/26/2014
Coronado Biosciences (CNDO) Reports Topline Results From Investigator Initiated Pilot Study Of TSO In Adults With Autism Spectrum Disorder 6/26/2014
Synthetic Biologics, Inc. (SYN) Reports That Licensor Cedars-Sinai Medical Center Finds Eradication Of Gut Methane Improves Insulin Sensitivity And Lipid Profiles In Study Of Pre-Diabetic, Obese Patients 6/25/2014
Antares Pharma, Inc. (ATRS) Release: Rapid Restoration And Consistent Maintenance Of Steady Blood Levels Achieved With Once-Weekly Subcutaneous Administration Of Testosterone Delivered With A Novel Auto Injector 6/25/2014
Quark Pharmaceuticals Inc. Announces First Patient Dosed In A Phase 2a Trial Evaluating QPI-1007 For Neuroprotection In Patients With Acute Primary Angle Closure Glaucoma 6/25/2014
NovaBiotics Ltd Release: Initiation Of A Phase IIa Clinical Study For Lynovex® In Cystic Fibrosis 6/25/2014
GenSpera Releases 2014 Biotechnology Industry Organization (BIO) International Presentation And HCC Clinical Trial Update For G-202 6/25/2014
NeuralStem Inc.'s NSI-189 Novel Neurogenic Compound Shows Significant Effect In Major Depressive Disorder 6/25/2014
Ohr Pharmaceutical (OHRP) Eye Drug Falls Short In Phase 2 Trial 6/24/2014
Ohr Pharmaceutical (OHRP) To Host Conference Call And Webcast To Discuss Squalamine Interim Phase 2 Data In Wet-AMD 6/24/2014
EnGeneIC Pty Ltd Unveils Clinical Development Strategy for EDV™ Nanocell Technology 6/24/2014
Actinium Pharmaceuticals, Inc. (ATNM.OB)’s Actimab-A And Alpha-Particle Immunotherapy Platform Further Validated At Society For Nuclear Medicine Annual Meeting 6/24/2014
Karyopharm Therapeutics (KPTI) Initiates Registration-Directed, Randomized Study Of Selinexor (KPT-330) In Older Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) 6/24/2014
Versartis, Inc. (VSAR) Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results 6/24/2014
XenoPort, Inc. (XNPT) Announces Initiation Of A Phase 2 Clinical Trial Of XP23829 In Patients With Psoriasis 6/23/2014
IP Group Plc – Portfolio Company Diurnal Reports Positive Phase 2 Results 6/23/2014
Genocea Biosciences Announces Positive Top-Line Phase 1 Results For Novel Universal Pneumococcus Vaccine Candidate GEN-004 6/23/2014
Madison Vaccines Announces Expansion Of A Phase 2 Clinical Trial For MVI-816, Its Lead DNA Vaccine For Prostate Cancer 6/23/2014
Prima Biomed (PRR.AX)'s CAN-002 CVac™ Trial Published In Journal For ImmunoTherapy Of Cancer 6/23/2014
GenSpera (GNSZ) Releases Updated Corporate Video: "Genspera Has Targeted Its Active Ingredient Thapsigargin To Kill Only The Cells We Select: Cancer" 6/23/2014
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/23/2014
Islet Sciences Highlights Remogliflozin Etabonate As Novel Treatment For Non-Alcoholic Steatohepatitis (NASH) 6/23/2014
Velocity Pharmaceutical Development, LLC And Tigercat Pharma, Inc. Announce Regulatory Clearance For Initiating Phase Ii Study With Vpd-737 In Prurigo Nodularis 6/23/2014
Inovio Pharmaceuticals (INO) Initiates Cervical Cancer Clinical Trial 6/23/2014
The European Medicines Agency And FDA Grant Orphan Drug Designation To PHARNEXT's PXT-3003 For The Treatment Of Charcot-Marie-Tooth Disease Type 1A 6/23/2014
VBL Therapeutics Announces Completion Of Enrollment In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 6/20/2014
Opko Health, Inc. To Hold Conference Call To Discuss Six Month Data From Phase 2 hGH-CTP Trial 6/20/2014
Northwest Biotherapeutics (NWBO) Biotechnology Industry Organization (BIO) Reaffirms DCVAX®-Direct Clinical Trial Interim Data Announcements 6/20/2014
Boehringer Ingelheim Corporation Initiates RE-CIRCUIT™ Trial, Evaluating Pradaxa® (dabigatran etexilate mesylate) In NVAF Patients Undergoing Ablation 6/20/2014
GenSpera CEO, Craig Dionne, To Present Update On Lead Drug Candidate G-202 At 2014 Biotechnology Industry Organization (BIO) International Convention 6/19/2014
Kadmon Corporation Initiates Phase 2a Portion Of KD020 Study In Autosomal Dominant Polycystic Kidney Disease 6/19/2014
Flexion Therapeutics (FLXN) Announces Positive Topline Results From Phase 2a Pharmacokinetic Trial With Lead Compound FX006 6/18/2014
MerLion Pharmaceuticals Pte Ltd Completes Recruitment In Finafloxacin Phase II cUTI Trial 6/18/2014
Asmacure Announces Top-Line Clinical Results For ASM-024 DPI In Ph 1/2a Trial 6/18/2014
Protalix Biotherapeutics, Inc. (PLX) Initiates Phase 2 Study With PRX-112, An Orally-Administered Enzyme Replacement Therapy For The Treatment Of Gaucher Disease 6/18/2014
Bellerophon Therapeutics Completes Enrollment For Its Phase 2 Trial Of Inopulse® For Treatment Of Pulmonary Arterial Hypertension (PAH) 6/17/2014
Mirati Therapeutics  (MRTX) Receives Orphan Drug Designation From U.S. FDA For Mocetinostat In Myelodysplastic Syndrome 6/17/2014
PsiOxus Therapeutics Limited Initiates "OCTAVE" Ovarian Cancer Study For Oncolytic Vaccine Enadenotucirev 6/17/2014
Grifols Completes Patient Enrollment In Its Phase2/3 Psoriasis Trial; Final Results Are Expected In Q1 2015 6/17/2014
Zealand Pharma  (ZEAL.CO) Provides Summary Of New Clinical Data And Information On Lyxumia® (Lixisenatide) And Lixilan Presented At The American Diabetes Association’s 74th Scientific Sessions 6/17/2014
Galena Biopharma  (GALE) Completes Enrollment In GALE-301 Phase 2a Clinical Trial In Ovarian And Endometrial Cancers 6/17/2014
Celsus Therapeutics (CLTX) Receives Approval From The Ministry Of Health Of Israel For Phase 2 Trial Of MRX-6 In Pediatric Atopic Dermatitis Patients 6/17/2014
Recro Pharma (REPH) Announces Dosing Of First Patient In Phase 2b Clinical Trial Of Dex-IN For Treatment Of Acute Pain Following Surgery 6/17/2014
Poxel’s Investigational Oral Agent - Imeglimin - Shows Unique Anti-diabetic Profile In Preclinical And Clinical Studies 6/16/2014
Novo Nordisk A/S (NVO) Release: New One-year Data of IDegLira Shows Glucose-Lowering Effect Was Maintained For People With Type 2 Diabetes 6/16/2014
Islet Sciences Presents Positive Clinical Results For Best-In-Class SGLT2 Inhibitor At American Diabetes Association Annual Meeting 6/16/2014
Cytokinetics, Inc. (CYTK) Announces Data Relating To Tirasemtiv Presented At The 2014 Annual Spinal Muscular Atrophy Conference 6/16/2014
Astex Pharmaceuticals (ASTX) Presents Final Results Of Phase 2 Study Of SGI-110 In Treatment Naïve Elderly Acute Myeloid Leukemia At The European Hematology Association Meeting 6/16/2014
Clovis Oncology (CLVS) Announces First Patient Enrolled In RUCAPANC Study 6/16/2014
ALK-Abello A/S’s Partner For Japan Announces Trial Results For House Dust Mite SLIT-Tablet 6/16/2014
Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy And Safety In Ground-Breaking Phase II Trigeminal Neuralgia Study 6/16/2014
Karyopharm Therapeutics (KPTI) Announces: FDA Considers The Effectiveness And Safety Technical Sections Complete To Support Conditional Approval For The New Animal Drug Application For Verdinexor (KPT-335) To Treat Lymphoma In Client Owned Dogs 6/16/2014
Sanofi (France) (SAN.PA)'s Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Liraglutide When Both Were Added To Insulin Glargine 6/16/2014
Isis Pharmaceuticals, Inc. (ISIS) Reports Final Phase 2 Data On ISIS-GCGR RX Showing Significant Reduction In Hba1c In Patients With Type 2 Diabetes 6/16/2014
NOXXON Pharma AG Presents Updates On Phase II Studies With Olaptesed Pegol (NOX-A12) In CLL And MM And Lexaptepid Pegol (NOX H94) In Anemic Cancer Patients 6/13/2014
TG Therapeutics, Inc. (MHA)' TG-1101 (Ublituximab) In Combination With Ibrutinib Demonstrates Compelling Clinical Activity And Safety Profile In Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL) And Mantle Cell Lymphoma (MCL) 6/13/2014
Amgen (AMGN)'s Psoriatic Arthritis Drug Brodalumab Maintains Efficacy After One Year Study 6/12/2014
Umecrine Mood's Premenstrual Dysphoric Disorder (PMDD) Drug Fails Phase 2 Study 6/12/2014
CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Initiates Randomized Phase 2 Trial Evaluating Tosedostat Plus Cytarabine For Older Patients With AML Or High-Risk MDS 6/12/2014
Generex Biotechnology Corporation (GNBT)/Antigen Express, Inc. (GNBT) Announce Interview Of MD Anderson Cancer Center's Dr. Elizabeth Mittendorf, Principal Investigator On Company's AE37 Phase IIb Breast Cancer Efficacy Trial 6/12/2014
Ambit Biosciences Announces Presentation Of Data From Clinical Investigations Of Quizartinib At The 19th Congress Of The European Hematology Association 6/12/2014
Ruthigen Cleared To Initiate Human Clinical Trials For RUT58-60 In The U.S. 6/12/2014
Receptos (RCPT) Surges As Lead Multiple Sclerosis Drug Meets Main Goal In Phase 2 Study; Stock Up +36.78% At Market Close (June 10, 2014) 6/11/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
Inovio Pharmaceuticals (INO) Clarifies Facts Of Its VGX-3100 Phase 2 Trial And Immunotherapy Technology 6/11/2014
Xenetic Biosciences Announces Dosing Of First Patient On Dialysis In Phase 2a Clinical Study Of Erepoxen® 6/11/2014
Portola Pharmaceuticals, Inc. Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy Andexanet Alfa and Enoxaparin 6/11/2014
Isis Pharmaceuticals, Inc. (ISIS) To Host Investor Event To Discuss ISIS-GCGR Rx Phase 2 Data Presented At The 2014 American Diabetes Association Scientific Sessions 6/11/2014
Caris Life Sciences Research Provides Key Clinical Insights On Immunotherapeutic Targets In A Broad Range Of Cancers 6/10/2014
Adamas Pharmaceuticals (ADMS) Announces Rater Training Data On ADS-5102 For Parkinson's Disease Patients With Levodopa-Induced Dyskinesia 6/10/2014
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Reports High Response Rates In Phase 2 Study Of Pracinostat In Front Line Acute Myeloid Leukemia 6/10/2014
Advaxis, Inc. Provides Business Update 6/10/2014
Quest PharmaTech Inc. Completes Patient Enrollment In Phase 2b Study Of Oregovomab For The Immunotherapy Of Ovarian Cancer 6/10/2014
OphthaliX Inc. Provides An Update On Its Clinical Developments And Strategic Plans 6/9/2014
FDA Grants Edison Pharmaceuticals, Inc.'s EPI-743 Orphan Status For Leigh Syndrome 6/9/2014
Karyopharm Therapeutics (KPTI) Announces Initiation Of Phase 2 Study Of Selinexor (KPT-330) In Patients With Hormone Refractory Prostate Cancer (SHIP Study) 6/9/2014
Versartis, Inc. (VSAR) To Hold Conference Call To Discuss Six Month VRS-317 Phase 2a VERTICAL Clinical Trial Results 6/9/2014
iCo Therapeutics Inc. Announces Top-Line Primary Endpoint Data From iCo-007 Phase 2 Ideal Study In Diabetic Macular Edema 6/9/2014
Halozyme Therapeutics, Inc. (HALO) Soars After FDA Lifts Hold On Pancreatic Cancer Trial; Stock Up +12% At Market Close (June 5, 2014) 6/6/2014
Breakthrough: AFFiRiS AG Claims A First In Alzheimer's Disease Therapy 6/6/2014
First Patient Enrolled In BrainStorm Cell Therapeutics Inc.'s Phase II ALS Trial At Massachusetts General Hospital 6/6/2014
Xeris Pharmaceuticals Announces Dosing Of First Patient In Phase 2 Clinical Trial Of Its Investigational Soluble Glucagon For The Treatment Of Mild-To-Moderate Hypoglycemia 6/6/2014
ImaginAb, Inc. Presents Initial Phase I/Iia Results For Prostate Imaging Agent At Society of Nuclear Medicine And Molecular Imaging (SNMMI) Annual Meeting 6/6/2014



//-->